{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06406348",
            "orgStudyIdInfo": {
                "id": "ALIA-1758-101"
            },
            "organization": {
                "fullName": "Aliada Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants",
            "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single Ascending Dose Trial to Assess the Safety, Tolerability and Pharmacokinetic Effects of ALIA-1758 in Healthy Participants",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "a-phase-trial-to-assess-safety-tolerability-and-pharmacokinetics-of-alia-in-healthy-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-06",
            "studyFirstSubmitQcDate": "2024-05-06",
            "studyFirstPostDateStruct": {
                "date": "2024-05-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-13",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Aliada Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female participants."
        },
        "conditionsModule": {
            "conditions": [
                "Alzheimer Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 52,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Active",
                    "type": "EXPERIMENTAL",
                    "description": "Single Ascending Dose (SAD) cohorts",
                    "interventionNames": [
                        "Drug: ALIA-1758"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Single Ascending Dose (SAD) cohorts",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ALIA-1758",
                    "description": "Intravenous or subcutaneous doses",
                    "armGroupLabels": [
                        "Active"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Intravenous or subcutaneous doses",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]",
                    "description": "Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs)",
                    "timeFrame": "Up to 85 days after dosing"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Cmax",
                    "description": "Cmax",
                    "timeFrame": "0-85 days after dosing"
                },
                {
                    "measure": "Pharmacokinetic parameters of ALIA-1758 in healthy subjects: T1/2",
                    "description": "elimination half-life (T1/2)",
                    "timeFrame": "0-85 days after dosing"
                },
                {
                    "measure": "Pharmacokinetic parameters of ALIA-1758 in healthy subjects: AUC",
                    "description": "Area Under Curve (AUC)",
                    "timeFrame": "0-85 days after dosing"
                },
                {
                    "measure": "Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Bioavailability",
                    "description": "Bioavailability after SC administration (F)",
                    "timeFrame": "0-85 days after dosing"
                },
                {
                    "measure": "Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Clearance",
                    "description": "Clearance (CL)",
                    "timeFrame": "0-85 days after dosing"
                },
                {
                    "measure": "Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Volume of distribution",
                    "description": "Volume of distribution (Vz)",
                    "timeFrame": "0-85 days after dosing"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Participants must understand the nature of the trial and must provide signed and dated written informed consent in accordance with local regulations before the conduct of any trial-related procedures.\n* Healthy as determined by the Investigator, based on a medical evaluation including medical history, physical examination, laboratory tests and electrocardiogram (ECG) recording. A participant with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if, in the opinion of the Investigator, the finding is (a) unlikely to introduce additional risk to the participant, (b) will not interfere with trial procedures or confound trial results, and (c) is not otherwise exclusionary (see Exclusion Criteria).\n* Body weight of at least 50.0 kg for men and 45.0 kg for women and Body Mass Index (BMI) within the range of 17.5-32.0 kg/m2 (inclusive) at Screening.\n\nKey Exclusion Criteria:\n\n* A history or presence of a clinically significant hepatic, biliary, renal, gastrointestinal, cardiovascular, endocrine, pulmonary, ophthalmologic, immunologic, hematologic, dermatologic, psychiatric, neurologic abnormality, or chronic urinary tract infections.\n* A clinically significant abnormality on physical examination, ECG, or laboratory evaluations at Screening or between Screening and (first) dose administration.\n* The participant is, in the opinion of the Investigator or Medical Monitor, unlikely to comply with the protocol or is unsuitable for any reason.\n\nOther criteria may apply",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "40 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "This is a single site clinical trial.",
                    "role": "CONTACT",
                    "phone": "210-635-1515",
                    "email": "participate@worldwide.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "J. Michael Ryan, M.D.",
                    "affiliation": "Aliada Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Worldwide Clinical Trials Early Phase Services, LLC",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78217",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Olutola Adetona, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000544",
                    "term": "Alzheimer Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000024801",
                    "term": "Tauopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3885",
                    "name": "Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23002",
                    "name": "Tauopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T2192",
                    "name": "Familial Alzheimer Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}